Effects of metformin on prognosis of type Ⅰ endometrial carcinoma patients complicated with type 2 diabetes mellitus
王雪,纪国欣,纪超,杨兴升
DOI: https://doi.org/10.3760/cma.j.cn371439-20191125-00045
2020-01-01
Abstract:Objective:To explore the effects of metformin on the prognosis of type Ⅰ endometrial carcinoma (EC) patients complicated with type 2 diabetes mellitus (T2DM).Methods:The clinical data of 45 type Ⅰ EC patients complicated with T2DM (T2DM group) and 147 type Ⅰ EC patients without diabetes mellitus (non-diabetes group) admitted to Qilu Hospital of Shandong University from January 2010 to December 2014 were retrospectively analyzed. The type Ⅰ EC patients with T2DM were divided into two groups, metformin group (
n=23, taking metformin to control blood glucose in normal range) and non-metformin group (
n=22, taking other hypoglycemic drugs or using insulin to control blood glucose in normal range). The clinicopathological characteristics of T2DM group and non-diabetes group were compared, and the effects of metformin on the prognosis of type Ⅰ EC patients with T2DM were analyzed.
Results:Compared with non-diabetes group, the type Ⅰ EC patients in T2DM group have the older onset age (
t=4.331,
P<0.001), more complicated with hypertension (
χ2=19.252,
P<0.001), later surgical pathological stage (
χ2=4.588,
P=0.032), higher histological grade (
χ2=6.069,
P=0.048), deeper myometrial infiltration (
χ2=7.743,
P=0.005) and higher incidence of lymph node metastasis (
χ2=4.885,
P=0.027). The median progression-free survival (PFS) (47.0 months
vs. 38.0 months) and median overall survival (OS) (52.0 months
vs. 41.0 months) in metformin group were significantly longer than those in non-metformin group (
χ2=10.899,
P=0.001;
χ2=10.090,
P=0.001). There was no significant difference in median PFS (47.0 months
vs. 46.0 months) and median OS (52.0 months
vs. 46.0 months) between metformin group and non-diabetes group (
χ2=0.791,
P=0.374;
χ2=0.836,
P=0.360). Cox multivariate analysis showed that the risk factors of PFS and OS in type ⅠEC patients were old onset age(
OR=2.128, 95%
CI: 1.361-3.328,
P=0.001;
OR=4.502, 95%
CI: 1.696-11.954,
P=0.003), late surgical pathological stage(
OR=2.231, 95%
CI: 1.437-3.462,
P=0.001;
OR=4.005, 95%
CI: 1.480-10.836,
P=0.006), high histological grade(
P=0.001;
P=0.017; G2
vs.G1:
OR=5.660, 95%
CI: 3.424-9.357,
P=0.001;
OR=5.763, 95%
CI: 1.666-19.938,
P=0.006), deep myometrial invasion(
OR=1.531, 95%
CI: 1.049-2.235,
P=0.027;
OR=3.759, 95%
CI: 1.890-7.476,
P=0.001), positive lymph node metastasis (
OR=11.277, 95%
CI: 2.774-45.838,
P=0.001;
OR=8.451, 95%
CI: 1.138-62.767,
P=0.037)and T2DM (
OR=1.897, 95%
CI: 1.096-3.281,
P=0.008;
OR=1.813, 95%
CI: 1.043-3.151,
P=0.012). Metformin was the protective factor of PFS (
OR=0.412, 95%
CI: 0.207-0.818,
P=0.002) and OS (
OR=0.455, 95%
CI: 0.228-0.905,
P=0.008) in type Ⅰ EC patients with T2DM.
Conclusion:Complication with T2DM is the negative factor on the prognosis of type Ⅰ EC patients. Intake of metformin can significantly improve the PFS and OS of type Ⅰ EC patients complicated with T2DM and improve the prognosis.